תאריך רישום: March 1, 1973

מסלול הגשה: מולקולה חדשה

יצרן: GSK CONSUMER HEALTHCARE SARL, SWITZERLAND

בעל רישום: HALEON CH ISRAEL LTD.

R01AA07 :ATC Code

4.1 Therapeutic indications Rapid relief of nasal congestion for up to ten hours in adults and adolescents aged 12 years and older.

תאריך רישום: November 10, 2004

מסלול הגשה: מולקולה חדשה

יצרן: CATALENT PHARMA SOLUTIONS, USA

בעל רישום: HALEON CH ISRAEL LTD.

M01AE01 :ATC Code

4.1. Therapeutic indications For the relief of mild to moderate pain associated with headache, toothache, backache, muscular and menstrual pains. Antipyretic. Anti-inflammatory for rheumatic diseases. For the treatment of pain associated with migraine.

תאריך רישום: March 2, 2009

מסלול הגשה: מולקולה חדשה

יצרן: BAYER AG, GERMANY

בעל רישום: BAYER ISRAEL LTD

G03AA12 :ATC Code

4.1 Therapeutic indications • Oral contraception. • Treatment of moderate acne vulgaris in women who seek oral contraception. • Treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who have chosen oral contraceptives as their method of birth control. The efficacy of YAZ for PMDD was not assessed beyond 3 cycles. YAZ has not been evaluated for treatment of PMS (premenstrual syndrome). The decision to prescribe YAZ should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with YAZ compares with other Combined Hormonal Contraceptives (CHCs) (see sections 4.3 and 4.4).

תאריך רישום: March 2, 2016

מסלול הגשה: מולקולה חדשה

יצרן: DELPHARM POZNAN S.A.,POLAND

בעל רישום: GLAXO SMITH KLINE (ISRAEL) LTD

N06AB05 :ATC Code

4.1 Therapeutic indications Treatment of (in adults): - Major Depressive Disorder - Obsessive Compulsive Disorder (OCD) - Panic Disorder with and without agoraphobia - Social Anxiety Disorders/Social phobia - Generalised Anxiety Disorder - Post-Traumatic Stress Disorder

תאריך רישום: October 22, 2009

מסלול הגשה: מולקולה חדשה

יצרן: FERRING INTERNATIONAL CENTER SA, SWITZERLAND

בעל רישום: FERRING PHARMACEUTICALS LTD

H01BA02 :ATC Code

4.1 Therapeutic indications Minirin tablets are indicated for Central Diabetes Insipidus, Nocturnal Enuresis (in patients from 5 years of age with normal ability to concentrate the urine) and for symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. The treatment must be started before the age of 65.

תאריך רישום: October 22, 2009

מסלול הגשה: מולקולה חדשה

יצרן: FERRING INTERNATIONAL CENTER SA, SWITZERLAND

בעל רישום: FERRING PHARMACEUTICALS LTD

H01BA02 :ATC Code

4.1 Therapeutic indications Minirin tablets are indicated for Central Diabetes Insipidus, Nocturnal Enuresis (in patients from 5 years of age with normal ability to concentrate the urine) and for symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. The treatment must be started before the age of 65.